Non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as a promising alternative to traditional anticoagulants, however there is one limitation, lack of readily available antidotes. Development of such agents t is required to reduce the risk of major bleeding.
Anticoagulant Reversal - Methodology
Species: rats
Rivaroxaban IV injection, application of filter paper soaked with FeCl3 to carotid artery
Timeline: in-life phase 1 day, total 3 weeks
Anticoagulant Reversal - Readouts & Application
Readouts:
Prothrombin Time (PT), Partial Thromboplastin Time (PTT)
Time to occlusion (TTO)
Application:
This elegant in-model is intended for preclinical efficacy testing of direct anticoagulant antidotes or clotting factor replacement. Option to assess safety of the new drug entity for the risk of thromboembolism is included.
